BDX - Becton Dickinson resumed at market perform at Raymond James

Raymond James has resumed coverage of Becton, Dickinson (BDX -0.7%) with a market perform rating to await a more attractive entry point. The firm did not set a target price. Analyst Jayson Bedford said that the stock's current valuation and year-to-date performance outperforming medtech peers supports Becton, Dickinson's (BDX -0.7%) current growth profile. "We see tuck-in deals as the primary strategy and do not expect larger, more complex deals," Bedford wrote. "R&D should remain stable, at ~6% of sales, which is expected to drive a doubling of new product revenue by FY25. BD also sports an above-peer dividend payout ratio, which we expect to continue." Read why Seeking Alpha contributor Khaveen Investments just gave Becton, Dickinson (BDX -0.7%) a strong buy rating.

For further details see:

Becton, Dickinson resumed at market perform at Raymond James